Get the Stockscreener App
13.63
14.11%
-2.24
After Hours:
16.22
2.59
+19.00%
Intellia Therapeutics Inc stock is traded at $13.63, with a volume of 8.46M.
It is down -14.11% in the last 24 hours and up +6.40% over the past month.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$15.87
Open:
$15.89
24h Volume:
8.46M
Relative Volume:
1.99
Market Cap:
$1.61B
Revenue:
$67.67M
Net Income/Loss:
$-412.69M
P/E Ratio:
-3.5619
EPS:
-3.8266
Net Cash Flow:
$-395.87M
1W Performance:
-8.83%
1M Performance:
+6.40%
6M Performance:
-46.76%
1Y Performance:
+66.63%
1-Day Range:
$13.42
$16.04
1-Week Range:
$13.42
$16.97
52-Week Range:
$6.83
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
13.63 | 1.61B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-11-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-28-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-27-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-27-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
CRISPR Therapeutics Stock Just Lost 12%: What Casgevy Must Prove Next - TechStock²
Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout - TechStock²
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits
Intellia Therapeutics (NTLA) Set to Release Phase 3 Data for Her - GuruFocus
Intellia to report Phase 3 CRISPR gene editing trial results Monday By Investing.com - Investing.com South Africa
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 - Intellia Therapeutics
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.6%Should You Sell? - MarketBeat
Intellia to report Phase 3 CRISPR gene editing trial results Monday - Investing.com Nigeria
Intellia plunges as Q3 updates indicate patient death in gene editing trial - MSN
Intellia Therapeutics (NTLA) Sector Trends | Q4 2025: Profit SurprisesRevenue Growth - Cổng thông tin điện tử tỉnh Lào Cai
NTLA stock rises 20% in 3 months: Here's what you should know - MSN
Intellia Therapeutics Amends By-Laws Following Recent Stock Surge - HarianBasis.co
(NTLA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Gene Editing Tools Market is expected to Hit US$ 1,700.05 Million - openPR.com
Intellia Therapeutics, Inc. (NTLA) Sees Moderate Buy Rating From Analysts - Insider Monkey
Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) - The National Law Review
Sumitomo Mitsui Trust Group Inc. Has $19.71 Million Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat
A Look At Intellia Therapeutics (NTLA) Valuation After Recent Share Price Volatility - Sahm
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 5.4%Should You Sell? - MarketBeat
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know - TradingView
NTLA Technical Analysis | Trend, Signals & Chart Patterns | INTELLIA THERAPEUTICS INC (NASDAQ:NTLA) - ChartMill
How The Narrative On Intellia Therapeutics (NTLA) Is Shifting After MAGNITUDE Hold Resolution - Yahoo Finance
Intellia Therapeutics Adopts Fourth Amended and Restated Bylaws - TipRanks
How (NTLA) Movements Inform Risk Allocation Models - Stock Traders Daily
Intellia Therapeutics Amends and Restates By-laws – Key Corporate Filing Details (April 2026) - Minichart
Intellia Therapeutics | 8-K: Current report - Moomoo
Intellia (NASDAQ: NTLA) revises bylaws on shareholder notices and federal forums - Stock Titan
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Clears MAGNITUDE Trials And Analyst Upgrade - Sahm
Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects - TechStock²
Jones Trading Downgrades Intellia Therapeutics (NTLA) - MSN
Why Intellia Therapeutics (NTLA) Is Up 14.2% After FDA Lifts MAGNITUDE Trial Holds and Upgrade - Sahm
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Intellia Therapeutics Announces Inducement Grants - National Today
Intellia Grants 67,150 RSUs to 13 New Hires - National Today
Intellia Therapeutics, Inc. (NTLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
13 new Intellia employees get 67,150 stock units over 3 years - Stock Titan
Gene Editing Market Set to Boom Rapidly by 2033 |CRISPR - openPR.com
Intellia Therapeutics Stock Price Forecast. Should You Buy NTLA? - StockInvest.us
Lawsuit for Investors in shares of Intellia Therapeutics, Inc. ( - GuruFocus
Trading Systems Reacting to (NTLA) Volatility - news.stocktradersdaily.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Intellia Therapeutics, Inc. (NTLA) Stock Forecasts - Yahoo Finance
Trending Industry Today: Intellia Therapeutics Leads Losses In Gene Editing Stocks - Moomoo
Intellia Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Intellia Therapeutics (NTLA) — Vanguard disaggregates holdings, parent reports 0 shares - Stock Titan
Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Strong-Buy at Truist Financial - MarketBeat
Risk Hedge: Is Intellia Therapeutics Inc a top pick in the sectorQuarterly Market Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Bank of America Securities Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA) - The Globe and Mail
Investors in Intellia Therapeutics, Inc. Should Contact Levi & Ko - The National Law Review
Aug Drivers: Does Intellia Therapeutics Inc have a sustainable dividendQuarterly Growth Report & Smart Swing Trading Alerts - baoquankhu1.vn
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.01%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):